Catherine Knupp - ZOETIS A President
ZOE Stock | EUR 167.50 0.48 0.29% |
President
Dr. Catherine A. Knupp is Executive Vice President, President Research and Development of Zoetis Inc. Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012. From 2005 to 2012, she served as Vice President of Pfizers Veterinary Medicine Research and Development business unit. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizers Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism. since 2012.
Age | 58 |
Tenure | 12 years |
Professional Marks | Ph.D |
Similar Executives
Found 1 records | PRESIDENT Age | ||
Mark Duff | Perma Fix Environmental Service | 60 |
ZOETIS A Leadership Team
Elected by the shareholders, the ZOETIS A's board of directors comprises two types of representatives: ZOETIS A inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ZOETIS. The board's role is to monitor ZOETIS A's management team and ensure that shareholders' interests are well served. ZOETIS A's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ZOETIS A's outside directors are responsible for providing unbiased perspectives on the board's policies.
Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply | ||
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director | ||
William Steere, Independent Director | ||
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations | ||
Willie Reed, Independent Director | ||
Linda Rhodes, Independent Director | ||
Frank DAmelio, Independent Director | ||
Robert Scully, Independent Director | ||
Glenn David, Chief Financial Officer, Executive Vice President | ||
Sanjay Khosla, Independent Director | ||
Catherine Knupp, Executive Vice President and Presidentident - Research and Development | ||
Michael McCallister, Non-Executive Independent Chairman of the Board | ||
Gregory Norden, Independent Director | ||
Louise Parent, Independent Director | ||
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | ||
Paul Bisaro, Independent Director | ||
Antoinette Leatherberry, Director |
ZOETIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ZOETIS A a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 71.14 B | |||
Price To Book | 15.38 X | |||
Price To Sales | 9.08 X | |||
Revenue | 8.08 B | |||
EBITDA | 3.34 B | |||
Net Income | 2.11 B | |||
Total Debt | 6.55 B | |||
Cash Flow From Operations | 1.91 B | |||
Price To Earnings To Growth | 3.58 X | |||
Number Of Employees | 26 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ZOETIS Stock Analysis
When running ZOETIS A's price analysis, check to measure ZOETIS A's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZOETIS A is operating at the current time. Most of ZOETIS A's value examination focuses on studying past and present price action to predict the probability of ZOETIS A's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZOETIS A's price. Additionally, you may evaluate how the addition of ZOETIS A to your portfolios can decrease your overall portfolio volatility.